Menarini Group’s elacestrant granted priority review by the US FDA for patients with ER+/HER2- advanced or metastatic breast cancer

Menarini

11 August 2022 - US FDA has assigned a Prescription Drug User Fee Act date of 17 February 2023.

The Menarini Group and Stemline Therapeutics today announced that the US FDA has accepted the Company’s new drug application for elacestrant, an investigational selective oestrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.

Read Menarini press release

Michael Wonder

Posted by:

Michael Wonder